Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Inhibikase Therapeutics Inc IKT

Healthcare Biotechnology
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing therapeutics for Parkinson’s disease and related disorders. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its lead program risvodetinib (also known as IkT-148009), an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson’s disease... see more

Current News (NDAQ:IKT)

Inhibikase Announces Expansion of Senior Leadership Team

GlobeNewswire February 24, 2025

Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company's Growth

GlobeNewswire February 18, 2025

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity

GlobeNewswire November 14, 2024

Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension

GlobeNewswire October 21, 2024

Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension

GlobeNewswire October 9, 2024

Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity

GlobeNewswire August 14, 2024

Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024

GlobeNewswire August 7, 2024

Inhibikase Therapeutics Completes Enrollment of the Phase 2 '201' Trial Evaluating Risvodetinib in Untreated Parkinson's Disease

GlobeNewswire June 17, 2024

Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs

GlobeNewswire June 5, 2024
View More News ››

Opinion & Analysis (NDAQ:IKT)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:IKT)

IKT Price Target Alert: $8.00. Issued by Jefferies

Just In: $IKT IKT Price Target Alert: $8.00. Issued by Jefferies2024-11-08 05:14:25 ET Dennis Ding from Jefferies issued a price target...
whytestocks - November 8, 2024

Inhibikase Therapeutics Announces Closing of up to $275 Mill

Just In: $IKT Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage...
whytestocks - October 21, 2024

Inhibikase Therapeutics, Inc. (NASDAQ:IKT): Advancing Innova

http://beyondspx.com/2024/08/01/inhibikase-therapeutics-inc-nasdaqikt-advancing-innovative-therapies-for-parkinsons-and-beyond/
MikeTester - August 2, 2024

Inhibikase Therapeutics Announces Pricing of Registered Dire

News; $IKT Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for...
whytestocks - May 20, 2024

My U.S w/l this a.m......

CS....HUBC...IKT...LIPO...THMO
Iseneschal - March 16, 2023

IKT ....Vols have declined

JUst an observation...no position Still watching !
Iseneschal - March 8, 2023
View more Bullboard ››

BioVaxys Technology Corp.

BioVaxys Technology Corp.

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving ...
View More »